Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
Study Details
Study Description
Brief Summary
Glioma disease is the most common primary malignant tumor of the central nervous system, with an annual incidence of about 3-8 people per 100,000 population, of which glioblastoma with the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective glioma database (3000 cases) integrating clinical information, magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to form a standardized database integrating clinical-prognostic information, magnetic resonance imaging and pathological results. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation and labeling process, and the expert consensus on database construction and use management of glioma diseases were established. Form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Glioma disease is the most common primary malignant tumor of the central nervous system, with an annual incidence of about 3-8 people per 100,000 population, of which glioblastoma with the highest degree of malignancy and the worst prognosis accounts for 70-75%. The construction goal of this project is to construct a multivariate retrospective glioma database (3000 cases) integrating clinical information, magnetic resonance imaging examination and molecular pathological results, and a prospective glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to form a standardized database integrating clinical-prognostic information, magnetic resonance imaging and pathological results. Based on the construction of the above standardized database, the specifications for the acquisition of cranial magnetic resonance images, the image segmentation and labeling process, and the expert consensus on database construction and use management of glioma diseases were established. Form a multimodal, large-capacity, high-quality, and rich medical imaging database that conforms to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On this basis, the data are dynamically updated, in-depth mining, and the classification and grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy evaluation system are formulated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Molecular pathology of glioma positive
|
Diagnostic Test: This study does not intervene in this process.
This study does not intervene in this process.
|
| Molecular pathology of glioma negative
|
Diagnostic Test: This study does not intervene in this process.
This study does not intervene in this process.
|
Outcome Measures
Primary Outcome Measures
- Establish standardized clinical-MRI -molecular markers database for glioma [2022.01-2024.12]
1) Collect clinical, MRI and molecular markers data of glioma patients; 2) Establish a standardized tumor labeling database; 3) Establish an automatic segmentation and recognition model of glioma
- Establish an accurate MRI-based deep-learning model for the prediction of glioma [2022.01-2024.12]
1) Build an accurate MRI-based deep-learning model with retrospective data. 2) The multicenter data was used to verify the repeatability and widespread use of the model again
Eligibility Criteria
Criteria
Inclusion Criteria:
-
(1) a clear diagnosis of glioma based on pathological results;
-
(2) The MRI sequence is complete and there are no obvious artifacts in the image;
-
(3) The patient signs an informed consent form
Exclusion Criteria:
-
(1) Suffering from other neurological diseases;
-
(2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or chemotherapy;
-
(3) Unable to complete clinical scoring and related laboratory tests, unable to complete follow-up;
-
(4) Unable to tolerate MRI examination; Poor image quality, such as motion artifacts.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Tiantan Hospital | Beijing | Beijing | China | 100053 |
Sponsors and Collaborators
- Beijing Tiantan Hospital
Investigators
- Principal Investigator: Yaou Liu, Doctor, Beijing Tiantan Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KY2022-078-04